key: cord-0708013-fuzdnvl2
authors: Bradley, James; Sbaih, Nadine; Chandler, Thomas R.; Furmanek, Stephen; Ramirez, Julio A.; Cavallazzi, Rodrigo
title: Pneumonia Severity Index and CURB-65 Are Good Predictors of Mortality in Hospitalized Patients with SARS-CoV-2 Community-Acquired Pneumonia
date: 2021-11-02
journal: Chest
DOI: 10.1016/j.chest.2021.10.031
sha: dbd641212460b3aaad1489f3e058c26949a3f89f
doc_id: 708013
cord_uid: fuzdnvl2

Background CURB-65 and Pneumonia Severity Index (PSI) are well-established clinical prediction rules for predicting mortality in patients hospitalized with community-acquired pneumonia (CAP). SARS-CoV-2 has emerged as a new etiologic agent for CAP, but the role of CURB-65 and PSI have not been established. Research Question How effective are CURB-65 and PSI at predicting in-hospital mortality from SARS-CoV-2 CAP compared to non-SARS-CoV-2 CAP? Can these clinical prediction rules be optimized to predict mortality in SARS-CoV-2 CAP by addition of procalcitonin and D-dimer? Study Design and Methods Secondary analysis of two prospective cohorts of patients with SARS-CoV-2 CAP or non-SARS-CoV-2 CAP from eight adult hospitals in Louisville, KY. Results The in-hospital mortality rate was 19% for patients with SARS-CoV-2 CAP and 6.5% for patients with non-SARS-CoV-2 CAP. For the PSI score, ROC analysis resulted in AUC of 0.82 (95% CI: 0.78 – 0.86) and 0.79 (95% CI: 0.77 – 0.80) for patients with SARS-CoV-2 CAP and non-SARS-CoV-2 CAP, respectively. For the CURB-65 score, ROC analysis resulted in AUC of 0.79 (95% CI: 0.75 – 0.84) and 0.75 (95% CI: 0.73 – 0.77) for patients with SARS-CoV-2 CAP and non-SARS-CoV-2 CAP, respectively. In SARS-CoV-2 CAP, addition of D-dimer (optimal cut-off 1813 ug/mL) and procalcitonin (optimal cut-off 0.19 ng/mL) to PSI and CURB-65 provided negligible improvement in prognostic performance. Interpretation PSI and CURB-65 can predict in-hospital mortality for patients with SARS-CoV-2 CAP and non-SARS-CoV-2 CAP comparatively. In patients with SARS-CoV-2 CAP, the inclusion of either D-dimer or procalcitonin to PSI or CURB-65 did not improve the prognostic performance of either score. In patients with CAP, regardless of etiology, PSI and CURB-65 remain adequate for predicting mortality in clinical practice.

blood gases were not obtained, we considered that PaO2 was greater than 60 and the arterial pH 111 was above 7.35 (and thus contributed no points to the PSI calculation). Radiographic pneumonia 112 was identified by new infiltrate as reported by a board-certified radiologist on CT-scan or chest 113 X-ray within 48 hours of admission. All data was stored in a Health Insurance Portability and 114 Accountability Act of 1996-protected online platform. 115

Continuous data are expressed as median values with interquartile ranges (25 th -75 th ), and 117 comparison between groups was assessed by the Mann-Whitney U test. Categorical variables are 118 expressed as a number (percentage) and compared by Chi-Squared tests. To assess the prognostic 119 J o u r n a l P r e -p r o o f ability of PSI and CURB-65 to predict mortality, both scores were calculated for each patient and 120 receiver operator characteristic (ROC) curves were generated. ROC analysis was performed and 121 values for area under the curve (AUC), sensitivity, specificity, positive predictive value, and 122 negative predictive value were calculated. Bootstrap 95% confidence intervals were calculated, 123 using replicates of 1000. 124 D-Dimer and procalcitonin were dichotomized at values that maximized sensitivity and 125 specificity for predicting mortality. The cut-off values for D-dimer and procalcitonin were found 126 to be 1813 ug/ml and 0.19 ng/ml respectively. These values were added to the PSI and CURB-65 127 scores to evaluate their impact on the predictive ability of these severity scores. To determine the 128 amount of improvement to the PSI and CURB-65 scores, the integrated discrimination 129 improvement was calculated for the addition of D-Dimer, procalcitonin, or both. 11 Analysis was 130 performed with R, version 3.4.0. 131 132 133

A total of 8081 patients were included in this study, with a total of 632 (8%) patients with 136 SARS-CoV-2 CAP. The median age of patients with SARS-CoV-2 CAP was 63, a total of 294 137 (47%) were male, 198 (31%) were black, and 74 (12%) were Hispanic. The baseline 138 characteristics for patients with SARS-CoV-2 CAP are summarized in Table 1 . Within the 139 SARS-CoV-2 CAP cohort, patients who died or pursued hospice care were older and had more 140 comorbidities overall, including a higher incidence of COPD (24% vs 13%), diabetes (48% vs 141 31%), heart failure (33% vs 12%), and renal disease (32% vs 16%) compared to those discharged 142 J o u r n a l P r e -p r o o f alive. Based on initial laboratory tests, patients with SARS-CoV-2 CAP who died or pursued 143 hospice care also had higher levels of D-dimer (1309 ug/ml vs 691 ug/ml) and procalcitonin 144 (0.48 ng/ml vs 0.10 ng/ml). D-dimer and procalcitonin was collected from 79.7% and 70.7% of 145 all patients in the SARS-CoV-2 CAP cohort. Baseline characteristics for patients with non-146 SARS-CoV-2 CAP from the University of Louisville Pneumonia Study cohort have been 147 published previously. 10 Comparison of baseline characteristics for patients with SARS-CoV-2 148 CAP and non-SARS-CoV-2 CAP is provided in e- Table 1 . 149

For patients within the SARS-CoV-2 CAP and non-SARS-CoV-2 CAP cohorts, the in-151 hospital mortality was assessed based on PSI risk class or CURB-65 score. Patients presenting 152 with SARS-CoV-2 CAP had a higher mortality rate in every PSI risk class and every CURB-65 153 score compared to patients with non-SARS-CoV-2 CAP (Figure 1 Figure 2 shows the ROC curves comparing PSI and CURB-65 in these 158 two cohorts. Table 2 shows the sensitivity, specificity, positive predictive value, and negative 159 predictive value for these patients. An additional post-hoc analysis was performed that compared 160 PSI, CURB-65, COVID-GRAM, Comorbidity-Age-Lymphocyte Count-Lactate Dehydrogenase 161 (CALL), and National Early Warning (NEWS2) scores in the SARS-CoV-2 CAP cohort (e- Fig  162   1 , e- Table 4 ). 163

J o u r n a l P r e -p r o o f Using the cut-off values for D-dimer and procalcitonin, the ROC analysis to evaluate the 165 prognostic ability of PSI and CURB-65 ( Figure 3 and Table 3) showed that there was no 166 improvement in performance of the two scoring systems by the addition of either D-dimer or 167 procalcitonin alone. There was a statistically significant improvement when adding both 168 laboratory values to the PSI or CURB-65, with an Integrated Discrimination Improvement of 169 0.03 (95% CI: 0.01-0.04) for the PSI and 0.03 (95% CI: 0.02-0.05) for the 171

This study shows that PSI and CURB-65 can be used to predict in-hospital mortality in 173 patients with SARS-CoV-2 CAP. In fact, their predictive ability in these patients compares 174

favorably to that in patients with non-SARS-CoV-2 CAP. A remarkable difference in the 175 positive predictive value between these two populations was found, likely attributable to the 176 increased prevalence of poor outcomes in patients with SARS-CoV-2 CAP compared to non-177 SARS-CoV-2 CAP. A high negative predictive value for both PSI and CURB-65 in SARS-CoV-178 2 CAP and non-SARS-CoV-2 CAP (> 94%) suggests that the optimal clinical benefit of these 179 scoring systems lie in their ability to detect patients at low risk for mortality. Although D-Dimer 180 and procalcitonin significantly increased the prognostic value of these indices, the observed 3% 181 improvement may not be clinically meaningful. 182

In resource-poor settings, a quick and accurate assessment of mortality risk allows 183 clinicians to triage and optimize care for those at highest risk, thus it is imperative that models be 184 developed, optimized, and evaluated in different patient populations. Several new predictive 185 models, recently reviewed by Wynants et al, have been proposed for patients with SARS-CoV-2 186 CAP, but the external validity of these models remains to be established, and they are at high risk 187 J o u r n a l P r e -p r o o f for bias as they were developed from a relatively small number of patients. 12 In our cohort of 188 patients with SARS-CoV-2 CAP, PSI remained the best clinical prediction score compared to 189 several novel prediction scores that have been specifically developed for SARS-CoV-2 CAP (e-190 Within the city of Louisville, the overall in-hospital mortality rate for adult patients with 209 non-SARS-CoV-2 CAP is 6.5%. 10 In our SARS-CoV-2 CAP cohort of patients, the in-hospital 210 illustrated in Figure 1 , irrespective of the PSI risk class or CURB-65 score, mortality was higher 212 for patients with SARS-CoV-2 CAP than for patients with non-SARS-CoV-2 CAP. In our study, 213 PSI was slightly superior to CURB-65 in its ability to predict in-hospital mortality. This is 214 consistent with prior work which showed slight improvement of PSI over CURB-65 in cohorts of 215 patients with SARS-CoV-2 CAP in China and Spain. 3, 18 The superiority of PSI is likely due to 216 the PSI model being heavily weighted by age and comorbidities, which are known risk factors 217 for mortality in SARS-CoV-2 CAP. 17,20,21 218

There are limitations in our study. Even though the study is multicenter and involved all 219 adult hospitals in Louisville, KY, it is still limited to a single city, which may impact its 220 generalizability. Another limitation is that D-dimer and procalcitonin were not collected in all 221

patients. There are no defined prognostic cut-off values for D-dimer and procalcitonin for 222 classification in patients with SARS-CoV-2 CAP, thus we used an ROC curve to generate cut-223 points that maximized sensitivity and specificity for our outcome. Additionally, the management 224 of SARS-CoV-2 CAP is constantly evolving, and our data represents outcomes based on 225 treatment provided to unvaccinated patients early in the pandemic when treatment options were 226 less defined. The data was prospectively collected, but this is a secondary analysis without 227 prospective validation of the models. Due to the retrospective nature of this study, 30-day 228 mortality was unavailable for too many patients in the SARS-CoV-2 CAP cohort to be deemed 229 useful in analysis due to our inability to follow up on patients after hospitalization. Arterial blood 230 gases were not obtained for all patients. However, further evaluation of PSI in SARS-CoV-2 231 CAP by non-linear imputation of PaO2 from SpO2 (for patients without arterial blood gases) did 232 not improve the predictability of in-hospital mortality-hospice care (e-Tables 5-6). 22 233

Our study also has several strengths. It relies on one of the largest datasets of patients 234 with CAP in the US. The data contains clinical variables that were prospectively collected by 235 research associates and validated. Additionally, recent work suggest that the city of Louisville is 236 representative of the overall US population with regards to sociodemographic, economic, and 237 health-related statistics. 23 238

Although still currently debated, it is thought that infection with SARS-CoV-2 may result 239 in a subsequent cytokine storm syndrome, similar to that which has been reported in other viral 240

infections. 24, 25 The addition of cytokines to risk models in future studies has the potential to 241 improve their predictive ability. Additionally, predictive models for ambulatory settings for 242 SARS-CoV-2 CAP would be instrumental in early triaging patients who would benefit from re-243 evaluation or early intervention to decrease mortality. Finally, more studies on implementation of 244 the available evidence, including predictive models, are needed. 245 246 Interpretation 247

In conclusion, our results illustrate that PSI and CURB-65 can predict in-hospital 248 mortality for patients with SARS-CoV-2 CAP with similar efficacy as compared to non-SARS-249

CoV-2 CAP. We also show that initial D-dimer and procalcitonin values do not substantially 250 improve the performance of PSI and CURB-65, thus the addition of these laboratory values for 251 the initial prognostic assessment of patients diagnosed with SARS-CoV-2 CAP is not warranted. 252

Our study results suggest that in patients with CAP, regardless of etiology, PSI and CURB-65 253 remain adequate for predicting mortality in clinical practice. J.B. and R.C. take responsibility for the content of the manuscript, including the data and 258 analysis. J.B., N.S, J.A.R, and R.C. contributed to study concept, data analysis, and 259 interpretation, writing, and editing of the manuscript. T.C., and S.F. contributed to data analysis 260 and interpretation, writing, and editing of the manuscript. 261 262

Funding/Support: J o u r n a l P r e -p r o o f 

Excess Deaths From COVID-19 294 and Other Causes in the US

Comparison of severity scores for COVID-19 patients with 297 pneumonia: a retrospective study

Performance of pneumonia severity 299 index and CURB-65 in predicting 30-day mortality in patients with COVID-19

Hematological findings and 302 complications of COVID-19

Clinical and immunological features of severe and 304 moderate coronavirus disease 2019

Procalcitonin in patients with severe coronavirus disease 2019 306 (COVID-19): A meta-analysis

Procalcitonin levels in COVID-19 patients

D-dimer as a biomarker for disease severity and mortality 310 in COVID-19 patients: a case control study

Characteristics and Outcomes of Adults 312 Hospitalized with SARS-COV-2 Community-Acquired Pneumonia in Louisville

Adults Hospitalized With Pneumonia in the 315 United States: Incidence, Epidemiology, and Mortality

Evaluating the added 318 predictive ability of a new marker: from area under the ROC curve to reclassification and 319 beyond

Prediction models for diagnosis and 321 prognosis of covid-19 infection: systematic review and critical appraisal

Endothelial cell infection and endotheliitis in 324 COVID-19

Autopsy Findings and Venous 326

Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Angiogenesis in Covid-19. The New England journal of medicine

The Emerging Threat of (Micro)Thrombosis in 332 COVID-19 and Its Therapeutic Implications

Risk factors of critical & mortal COVID-19 cases: A 334 systematic literature review and meta-analysis

Severity Scores in COVID-19 336 Pneumonia: a Multicenter, Retrospective, Cohort Study

Severity assessment tools for 341 predicting mortality in hospitalised patients with community-acquired pneumonia. 342 Systematic review and meta-analysis

Characteristics of and Important Lessons From the Coronavirus 344 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases 345 From the Chinese Center for Disease Control and Prevention

Nonlinear Imputation of Pao2/Fio2 From 348

Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome

The City of Louisville Encapsulates the Unites 351

Characterization of the Inflammatory 354 Response to Severe COVID-19 Illness

Influenza infection, SARS, MERS and 357 COVID-19: Cytokine storm -The common denominator and the lessons to be learned

/mm3)

ug/ml) b 1309